Search

everythinglearnresearchcommunity

for

Search:↓

The conclusion is that the risk of losing significance in meta-analysis results increases with smaller effects and more missing data, and using the median standard deviation for imputation is recommended.

People with atopic dermatitis are more likely to develop other skin conditions due to shared genetics and immune pathways.

Many women experience significant hair loss during menopause, and topical minoxidil is an effective treatment.

Biotin doesn't help hair growth in healthy people and can cause health risks if overused.

Systematic reviews on platelet-rich plasma therapy for hair loss have many quality issues.

Early-onset male baldness is significantly linked to a higher risk of metabolic syndrome.

Spironolactone is safe for breast cancer survivors with alopecia and does not increase cancer risk.

Finasteride safety data in trials may be underreported or misrepresented.

Platelet-rich plasma combined with other treatments improves acne scars better than those treatments alone.

5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.

Alopecia patients have higher heart disease risk; statins and finasteride may help.

Finasteride toxicity information is limited, poor quality, and biased.

Finasteride helps hair growth but may cause sexual side effects.

Insulin sensitizers may slightly reduce hirsutism but are less effective than other treatments.

Finger length ratios are not linked to the number of specific gene repeats affecting testosterone sensitivity.

Oriental herbal medicine with moxibustion may improve pregnancy rates and other symptoms in PCOS, but more high-quality research is needed.

Androgenetic alopecia negatively affects quality of life and self-esteem, especially in women, but not depression.

Spironolactone does not increase cancer risk and may lower prostate cancer risk, but more research is needed.

Dutasteride is the most effective hair loss treatment after 24 weeks, but finasteride leads to the most hair growth after 48 weeks.

JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.

Imiquimod may be a better non-surgical treatment for cervical pre-cancer, but its effectiveness for vaginal pre-cancer is unclear, and it has some side effects.

Combination therapies are more effective for treating androgenetic alopecia than single treatments.

Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.

Activated PRP injections are effective in treating hair loss and improving hair density.

People with Alopecia Areata are more likely to have certain health issues like ulcerative colitis and type 1 diabetes, but less likely to have others like hypertension and type 2 diabetes.

Hormone treatment before hypospadias surgery can increase penis size and reduce surgery complications.

Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might reduce it. AST decreases recurrence-free survival but doesn't affect overall survival or progression-free survival. More research is needed to understand AST's benefits.

Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.

Dutasteride is more effective than finasteride for treating BPH without extra safety risks.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.